Labcorp announced a strategic investment in Cofactor Genomics on December 15, 2025, to broaden its oncology diagnostics portfolio and accelerate the nationwide rollout of the company’s RNA‑based OncoPrism immunotherapy‑response test.
The OncoPrism assay uses sequencing and machine learning to quantify immune engagement and predict patient response to immune checkpoint inhibitors, outperforming traditional PD‑L1 biomarkers and offering clinicians a more precise tool for selecting immunotherapy candidates.
Labcorp’s CEO Adam Schechter said the partnership “broadens patient access to cutting‑edge precision diagnostics and strengthens our specialty testing moat.” The deal is part of Labcorp’s broader strategy to grow high‑complexity oncology assays, which command premium pricing and drive margin expansion.
By integrating Cofactor’s tests into its existing specialty testing platform, Labcorp will offer clinicians a more comprehensive suite of precision diagnostics, positioning the company to capture a larger share of the rapidly expanding immunotherapy‑guided oncology testing market and to compete more effectively against Quest Diagnostics and other laboratory service providers.
The financial terms of the investment were not disclosed, but the partnership is expected to accelerate Cofactor’s expansion and broaden patient access to its diagnostics across U.S. cancer care networks, reinforcing Labcorp’s focus on oncology and precision medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.